Sign up
Log in
$TOCKHOLDER ALERT: The M&A Class Action Firm Continues Its Investigation Into The Merger - BRDG, AKYA, CKPT, QTRX
Share
Listen to the news

NEW YORK, April 18, 2025 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating:

  • Bridge Investment Group Holdings Inc. (NYSE: BRDG), relating to the proposed merger with Apollo. Under the terms of the agreement, Bridge stockholders and Bridge OpCo unitholders will receive 0.07081 shares of Apollo stock for each share of Bridge Class A common stock and each Bridge OpCo Class A common unit, respectively.

Click here for more https://monteverdelaw.com/case/bridge-investment-group-holdings-inc-brdg/. It is free and there is no cost or obligation to you.

  • Akoya Biosciences, Inc. (NASDAQ: AKYA), relating to the proposed merger with Quanterix. Under the terms of the agreement, Akoya shareholders will receive 0.318 shares of Quanterix common stock for each share of Akoya common stock owned. Akoya shareholders will own approximately 30% of the combined company.

ACT NOW. The Shareholder Vote is scheduled for May 13, 2025.

Click here for more https://monteverdelaw.com/case/akoya-biosciences-inc-akya/. It is free and there is no cost or obligation to you.

  • Checkpoint Therapeutics, Inc. (NASDAQ: CKPT), relating to the proposed merger with Sun Pharmaceutical Industries Limited. Under the terms of the agreement, Checkpoint stockholders will receive, for each share of common stock they hold, a cash payment of $4.10, and a non-transferable contingent value right entitling the stockholder to receive up to $0.70 in cash.

Click here for more https://monteverdelaw.com/case/checkpoint-therapeutics-inc-ckpt/. It is free and there is no cost or obligation to you.

  • Quanterix Corporation (NASDAQ: QTRX), relating to the proposed merger with Akoya Biosciences. Under the terms of the agreement, Akoya shareholders will be given 0.318 shares of Quanterix common stock for each share of Akoya common stock owned.

ACT NOW. The Shareholder Vote is scheduled for May 13, 2025.

Click here for more https://monteverdelaw.com/case/quanterix-corporation-qtrx/. It is free and there is no cost or obligation to you.

Monteverde & Associates PC Logo

NOT ALL LAW FIRMS ARE THE SAME. Before you hire a law firm, you should talk to a lawyer and ask:

  1. Do you file class actions and go to Court?
  2. When was the last time you recovered money for shareholders?
  3. What cases did you recover money in and how much?

About Monteverde & Associates PC

Our firm litigates and has recovered money for shareholders…and we do it from our offices in the Empire State Building. We are a national class action securities firm with a successful track record in trial and appellate courts, including the U.S. Supreme Court. 

No company, director or officer is above the law. If you own common stock in any of the above listed companies and have concerns or wish to obtain additional information free of charge, please visit our website or contact Juan Monteverde, Esq. either via e-mail at jmonteverde@monteverdelaw.com or by telephone at (212) 971-1341.

Contact:

Juan Monteverde, Esq.

MONTEVERDE & ASSOCIATES PC

The Empire State Building

350 Fifth Ave. Suite 4740

New York, NY 10118

United States of America

jmonteverde@monteverdelaw.com

Tel: (212) 971-1341

Attorney Advertising. (C) 2025 Monteverde & Associates PC. The law firm responsible for this advertisement is Monteverde & Associates PC (www.monteverdelaw.com). Prior results do not guarantee a similar outcome with respect to any future matter.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/tockholder-alert-the-ma-class-action-firm-continues-its-investigation-into-the-merger--brdg-akya-ckpt-qtrx-302432059.html

SOURCE Monteverde & Associates PC

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.